NCT01806324已完成1 期
A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 主要终点
- Cmax
研究概览
简要总结
The objective of this study is:
To evaluate the pharmacokinetics and safety of an experimental combination tablet containing 20 mg atorvastatin and 50 mg losartan potassium when administered orally as a single dose to healthy male subjects, compared with the concomitant administration of 20 mg atorvastatin and 50 mg losartan potassium tablets.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects between 19 and 50 years of age, inclusive.
- •Subjects who weigh at least 121 pounds (55 kg), and are within ± 20% of their of ideal body weight (IBW). IBW (kg) = [height (cm) - 100] x 0.
- •Subjects who don't have any congenital or chronic disease.
- •Subjects who don't have any clinically significant abnormality on vital sign measurement, physical examination, clinical lab test, and ECG test at Screening.
- •Subjects who are able to read and understand the consent form.
排除标准
- •Subjects who have any history or presence of hypersensitivity to HMG-CoA reductase inhibitors such as atorvastatin or angiotensin receptor blockers such as losartan.
- •Subjects who have any medical history that may affect the absorption, distribution, metabolism, and excretion of study drugs (e.g., cardiovascular, respiratory, renal, endocrinal, hematological, digestive, neurological, or psychiatric disease).
- •Subjects who have a creatinine clearance < 80 mL/min, which is calculated by Cockcroft-Gault equation: (140 - age) x (Wt in kg) / (72 x sCr).
- •Subjects who had a severe injury or surgery within 4 weeks prior to Screening.
- •Subjects who have a positive drug screen.
- •Subjects who take any prescription or herbal drug within 1 week prior to Screening.
- •Subjects who take any over-the counter (OTC) drug, which may affect this study or the subject's safety according to the judgment of investigator, at Screening.
- •Subjects who take any herbal drug containing St. John's Wort or other drugs, which are metabolized by CYP3A4 enzyme or inhibit or stimulate CYP enzyme (e.g., itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitor, nefazodone) within 4 weeks prior to Screening.
- •Subjects who have abnormal meal pattern that may affect the absorption, distribution, metabolism, and excretion of study drugs (e.g., taking grapefruit juice over 1 L per day).
- •Subjects who received an investigational product within 4 weeks prior to Screening.
- •Subjects who have donated blood within 6 weeks prior to Screening.
- •Subjects who consume alcohol over 21 units per week (1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol) and can't accept the prohibition of alcohol during this clinical study.
- •Subjects who smoke more than 10 cigarettes per day.
- •Subjects who have low blood pressure (systolic ≤ 100 mmHg or diastolic ≤ 65 mmHg) or high blood pressure (systolic ≥ 150 mmHg or diastolic ≥ 95 mmHg) at Screening.
- •Subjects who test positive on serology HBsAg, HCV Ab, HIV Ab or VDRL at Screening.
- •Subjects who have active liver disease or elevated serum transaminase level higher than 3 times of upper limit of normal.
- •Subjects who have the inability in the opinion of the investigator to comply with the protocol.
研究组 & 干预措施
HL040XC(Atorvastatin+Losartan)
Experimental
HL040XC lag time released combination drug
干预措施: HL040XC (Drug)
Losartan + Atorvastatin
Active Comparator
Coadministration group
干预措施: Losartan + Atorvastatin (Drug)
结局指标
主要结局
Cmax
时间窗: 0 ~ 48hr
To evaluate its bioequivalency in Cmax and AUC of each test group
AUC
时间窗: 0~48HR
To evaluate bioequvalency of each group
次要结局
未报告次要终点
研究者
相似试验
已完成
4 期
A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese ParticipantsHealthyNCT01810887Janssen Pharmaceutical K.K.8
已完成
2 期
Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and PostpartumHIV InfectionsNCT03386578National Institute of Allergy and Infectious Diseases (NIAID)780
已完成
1 期
Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of of HZBio1 in Healthy SubjectsHealthy ParticipantsNCT04765995Hangzhou Grand Biologic Pharmaceutical, Inc.40
撤回
1 期
Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With InfluenzaInfluenzaNCT01063933National Institute of Allergy and Infectious Diseases (NIAID)
招募中
1 期
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune DiseasesAutoimmune DiseasesNCT06747156Ruijin Hospital66